boehringer ingelheim glp-1 π¨ Survodutide, a weekly subcutaneous dual GLP-1/glucagon agonist, posts new top-line Phase 3 results today π SYNCHRONIZE-1: Adults with overweight/obesity randomized to survodutide vs. placebo for 76 weeks βοΈ 16.6% weight loss ( Who should actually take a
Pay in 4 interest-free payments of $6.11 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 4 - Aug 9



:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)


















